SRR9879265
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.520
- G2M_CHECKPOINT+0.460
- E2F_TARGETS+0.430
- PROTEIN_SECRETION+0.310
- UV_RESPONSE_DN+0.280
- SPERMATOGENESIS+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.210
- HEDGEHOG_SIGNALING+0.200
- MYC_TARGETS_V1+0.190
- MYC_TARGETS_V2+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.440
- COAGULATION-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- ESTROGEN_RESPONSE_EARLY-0.390
- ESTROGEN_RESPONSE_LATE-0.380
- APICAL_SURFACE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20120131.TNBC | — | E | 0.903 |
| 2 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.902 |
| 3 | BS_4CP4T22V | medulloblastoma | — | 0.893 |
| 4 | s0122172 | — | — | 0.892 |
| 5 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.891 |
| 6 | MDT-AP-3021 | Med | Medulloblastoma | 0.888 |
| 7 | SRR5088887 | — | — | 0.886 |
| 8 | MDT-AP-3311 | Med | Medulloblastoma | 0.879 |
| 9 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.878 |
| 10 | SRR8518213 | — | D | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |